Imatinib, a potent and selective inhibitor of the protein tyrosine kinase BCR-ABL, has shown significant clinical activity in chronic myeloid leukemia (CML), producing durable responses and prolonged survival [1,2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.